We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.1B
AUM Growth
+$93.7M
Cap. Flow
+$96.1M
Cap. Flow %
8.76%
Top 10 Hldgs %
40.44%
Holding
102
New
24
Increased
37
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
2
ABT icon
Abbott
ABT
+$15.9M
3
NTRA icon
Natera
NTRA
+$12.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.8M
5
MMSI icon
Merit Medical Systems
MMSI
+$12.7M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.2M
2
MDT icon
Medtronic
MDT
+$20.5M
3
MRK icon
Merck
MRK
+$19.8M
4
CNC icon
Centene
CNC
+$18.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.1%

No holdings matched the selected filter criteria.

1 2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, PFM Health Sciences held 102 positions worth $1.1B, up 9.3% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $96.1M of net new capital in Q1 2026, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Abbott: 140,432 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $18.9M trimmed.

  • PFM Health Sciences's largest Q1 2026 buy was Abbott: 140,432 shares worth $14.4M.
  • PFM Health Sciences added most to Jazz Pharmaceuticals in Q1 2026, an estimated $22.3M increase.
  • PFM Health Sciences's biggest Q1 2026 reduction was Centene, cutting an estimated $18.9M.
  • PFM Health Sciences fully exited ADMA Biologics in Q1 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $1.1B portfolio in Q1 2026.
  • PFM Health Sciences opened 24 new positions and closed 19 in Q1 2026.
  • PFM Health Sciences's portfolio value rose 9.3% quarter-over-quarter to $1.1B.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.